11 sep: Danmark: Inflation fortsætter høj stigningstakt for anden måned i..
11 sep: Lundbeck/fmd: Unikt karrierespring får Kåre Schultz til at stoppe
11-09-2017 09:15:06

Principal Investigator Dr. James Gulley to Provide Presentation Entitled "Therapeutic Vaccines in Prostate Cancer" at the ESMO 2017 Congress

Relateret indhold
23 apr - 
Bavarian-aktien har oplevet markant shortangreb efter r..
20 apr - 
Fredagens aktier: Mærsk i fuld fart frem - Vestas og Ba..
20 apr - 
Bavarian: Udenlandske kapitalfonde øger væddemålet på k..
Relateret debat
13:55 - 
Er der nogen der ved om udenlandske fx. amerikanske bli..
13:19 - 
der er en på siden her der kan se tilbage på AB netto s..
11:41 - 
der er altid nogle der vil låne dem aktierne og de bliv..

MADRID, September 11, 2017 - This morning at the European Society for Medical Oncology (ESMO) 2017 Congress, Dr. James Gulley, Chief, Genitourinary Malignancies Branch, Senior Investigator, Head, Immunotherapy Section, Director, Medical Oncology Service, CCR Office of the Clinical Director, NCI, and Principal Investigator on PROSPECT, the Phase 3 study of PROSTVAC, will provide a presentation entitled "Therapeutic Vaccines in Prostate Cancer", including several blinded observations of the ongoing PROSPECT Phase 3 study.

As part of the presentation Dr. Gulley will highlight the blinded Kaplan-Meier curve for overall survival (OS) in the PROSPECT study for all patients, active and placebo. Dr. Gulley will also show this blinded median OS broken down by various geographies.

As the PROSPECT study is still ongoing, with full data expected in 2017, the data presented today are preliminary and fully blinded to the company and investigators and as such, no firm conclusions can be drawn about the eventual outcome of the PROSPECT Phase 3 study.

Following this presentation, a copy of the slides presented by Dr. Gulley can be found by visiting www.bavarian-nordic.com under "Investors > Events & Presentations".

About the PROSPECT study

The PROSPECT study is a global randomized, double-blind, placebo-controlled study in patients with asymptomatic or minimally symptomatic mCRPC. The trial is being conducted under a Special Protocol Assessment agreement with the FDA. The primary objective of the study is to determine whether the overall survival of patients receiving PROSTVAC (with or without the addition of granulocyte macrophage colony-stimulating factor; GM-CSF), is superior to that of patients receiving placebo.

The study completed recruitment in January of 2015 with a final enrolment of 1,297 men.  Based on the dosing schedule of PROSTVAC, all men would have completed their course of therapy no later than June 2015.

Three pre-specified interim analyses of data have been integrated into the statistical plan to evaluate whether the trial should continue as planned, or potentially be stopped early for efficacy or futility. Two of these interim analyses have already occurred, with the conclusion that the study should continue without modification. The third interim analysis is expected to occur in September 2017 with final data expected in the fourth quarter of 2017.

About Bavarian Nordic

Bavarian Nordic is a fully integrated biotechnology company focused on the development, manufacturing and commercialization of cancer immunotherapies and vaccines for infectious diseases, based on the Company's live virus vaccine platform. Through long-standing collaborations, including a collaboration with the U.S. government, Bavarian Nordic has developed a portfolio of vaccines for infectious diseases, including the non-replicating smallpox vaccine, IMVAMUNE®, which is stockpiled for emergency use by the United States and other governments. The vaccine is approved in the European Union (under the trade name IMVANEX®) and in Canada. Bavarian Nordic and its strategic partner Janssen are developing an Ebola vaccine regimen, and therapeutic vaccines for HPV, HBV and HIV. Additionally, in collaboration with the National Cancer Institute, Bavarian Nordic has developed a portfolio of active cancer immunotherapies, including PROSTVAC®, which is currently in Phase 3 clinical development for the treatment of advanced prostate cancer. The company has partnered with Bristol-Myers Squibb for the potential commercialization of PROSTVAC. For more information visit www.bavarian-nordic.com or follow us on Twitter @bavariannordic.

Contacts

Rolf Sass Sørensen

Vice President Investor Relations (EU)

Tel: +45 61 77 47 43

Seth Lewis

Vice President Investor Relations (US)

Tel: +1 978 341 5271

Press Release

2017-09-11-en


This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Bavarian Nordic A/S via Globenewswire

Vedhæftet fil: 2017-09-11-en.pdf

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
19 apr
BAVA
      Vedr. shortsqeeze mm. og den ekstreme kursmanipulation der dagligt foregår på Nasdaq Kbhvn. T..
19
18 apr
BAVA
Jeg tror nok der er nogen, der sidder lidt længere ude på stolen i dag. Det skulle ikke undre mig om..
11
17 apr
BAVA
Aamund har alle dage været rigtig god til at tale.........for sin syge moster. Jeg har ingen fidus t..
11
17 apr
BAVA
Nu har AA aldrig været kendt for, at være ramt af biotek aktie-pessimisme, så med en skovl salt til,..
9
21 apr
BAVA
Er en velkendt måde for spekulanter og pensionskasser at tjene penge på. Hvis frosten kommer tjener ..
8
20 apr
BAVA
Det er ikke hans skyld. Det er disse shortere der bare skal have dens mindste anledning til at sælge..
5
18 apr
BAVA
@Henry1, jeg må indrømme, at det af og til er bare en anelse trættende at læse dine Bavarian indlæg...
5
08:19
BAVA
Summary Posted: 04/2018 Combination immunotherapy clinical trial for prostate cancer patients with r..
4
18 apr
BAVA
GSA Capital Partners LLP holds a short position at 0.54 % in shares issued by Bavarian Nordic A/S Gi..
4
17 apr
BAVA
Ja kan ikke rigtig lide AA kommentar omkring det kortsigtet, det langsigtet er jeg 100% enig i.   Ko..
4

DFDS får ny færge til Den Engelske Kanal

24-04-2018 10:41:49
Rederiet DFDS har indgået en tiårig bareboat charteraftale med Stena RoRo om en nybygget færge af typen ro-pax til levering i begyndelsen af 2021.Det skriver selskabet i en pressemeddelelse. Færgen skal sejle på Den Engelske Kanal, hvor den bliver en af seks færger, der sejler på to ruter. Den nye færge skal erstatte den ældste af slagsen, der blev taget i bygget i 1991. Den nye færge får højere f..

Aktier/tendens: DSV og Genmab løber med opmærksomheden

24-04-2018 08:26:35
Der er lagt op til en stille åbning på det danske aktiemarked tirsdag morgen, hvor investorerne vil have fokus på DSV efter regnskabet fra en af selskabets nærmeste rivaler, mens Genmab har fået løftet kursmålet hos JPMorgan.Det amerikanske aktiemarked faldt en spids efter dansk børslukketid mandag, men tirsdag morgen peger de asiatiske aktier op. Samtidig stiger futures marginalt for det tyske DA..

Tivoli/CEO: Ny sæson og Tivoli Hjørnet øger omsætningen

23-04-2018 13:39:42
Den nye sæson hos forlystelsesparken Tivoli, Vinter I Tivoli, har sammen med åbningen af Tivoli Hjørnet bidraget til, at omsætningen er steget i første kvartal 2018.Det vurderer Lars Liebst, der er administrerende direktør i Tivoli. - Vi har haft åbent til Vinter i Tivoli og åbnet vores hjørne, og det har været gode ting. Det kan man se på omsætningen, siger Lars Liebst til Ritzau Finans.Nettoomsæ..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Bavarian-aktien har oplevet markant shortangreb efter regnskab
2
Aktier/tendens: DSV og Genmab løber med opmærksomheden
3
Mandagens aktier: Tryg tog toppen i grønt C25
4
GE har fundet rugekassen til sin nye gigantmølle på 12 MW
5
Legetøjsgigant vender på børsen efter ledelseskommentarer - NY

Relaterede aktiekurser

Bavarian Nordic A/S 164,40 -1,1% Fald i aktiekurs

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2018  Disclaimer Cookie- og privatlivspolitik
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
24. april 2018 14:37:43
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20180423.5 - EUROWEB4 - 2018-04-24 14:37:43 - 2018-04-24 14:37:43 - 1 - Website: OKAY